Cargando…
The Prostaglandin E2 Receptor EP4 Promotes Vascular Neointimal Hyperplasia through Translational Control of Tenascin C via the cAPM/PKA/mTORC1/rpS6 Pathway
Prostaglandin E2 (PGE2) is an important metabolite of arachidonic acid which plays a crucial role in vascular physiology and pathophysiology via its four receptors (EP1-4). However, the role of vascular smooth muscle cell (VSMC) EP4 in neointimal hyperplasia is largely unknown. Here we showed that V...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9454981/ https://www.ncbi.nlm.nih.gov/pubmed/36078128 http://dx.doi.org/10.3390/cells11172720 |
_version_ | 1784785480791883776 |
---|---|
author | Xu, Hu Fang, Bingying Bao, Chengzhen Mao, Xiuhui Zhu, Chunhua Ye, Lan Liu, Qian Li, Yaqing Du, Chunxiu Qi, Hang Zhang, Xiaoyan Guan, Youfei |
author_facet | Xu, Hu Fang, Bingying Bao, Chengzhen Mao, Xiuhui Zhu, Chunhua Ye, Lan Liu, Qian Li, Yaqing Du, Chunxiu Qi, Hang Zhang, Xiaoyan Guan, Youfei |
author_sort | Xu, Hu |
collection | PubMed |
description | Prostaglandin E2 (PGE2) is an important metabolite of arachidonic acid which plays a crucial role in vascular physiology and pathophysiology via its four receptors (EP1-4). However, the role of vascular smooth muscle cell (VSMC) EP4 in neointimal hyperplasia is largely unknown. Here we showed that VSMC-specific deletion of EP4 (VSMC-EP4) ameliorated, while VSMC-specific overexpression of human EP4 promoted, neointimal hyperplasia in mice subjected to femoral artery wire injury or carotid artery ligation. In vitro studies revealed that pharmacological activation of EP4 promoted, whereas inhibition of EP4 suppressed, proliferation and migration of primary-cultured VSMCs. Mechanically, EP4 significantly increased the protein expression of tenascin C (TN-C), a pro-proliferative and pro-migratory extracellular matrix protein, at the translational level. Knockdown of TN-C markedly suppressed EP4 agonist-induced VSMC proliferation and migration. Further studies uncovered that EP4 upregulated TN-C protein expression via the PKA/mTORC1/Ribosomal protein S6 (rpS6) pathway. Together, our findings demonstrate that VSMC EP4 increases TN-C protein expression to promote neointimal hyperplasia via the PKA-mTORC1-rpS6 pathway. Therefore, VSMC EP4 may represent a potential therapeutic target for vascular restenosis. |
format | Online Article Text |
id | pubmed-9454981 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-94549812022-09-09 The Prostaglandin E2 Receptor EP4 Promotes Vascular Neointimal Hyperplasia through Translational Control of Tenascin C via the cAPM/PKA/mTORC1/rpS6 Pathway Xu, Hu Fang, Bingying Bao, Chengzhen Mao, Xiuhui Zhu, Chunhua Ye, Lan Liu, Qian Li, Yaqing Du, Chunxiu Qi, Hang Zhang, Xiaoyan Guan, Youfei Cells Article Prostaglandin E2 (PGE2) is an important metabolite of arachidonic acid which plays a crucial role in vascular physiology and pathophysiology via its four receptors (EP1-4). However, the role of vascular smooth muscle cell (VSMC) EP4 in neointimal hyperplasia is largely unknown. Here we showed that VSMC-specific deletion of EP4 (VSMC-EP4) ameliorated, while VSMC-specific overexpression of human EP4 promoted, neointimal hyperplasia in mice subjected to femoral artery wire injury or carotid artery ligation. In vitro studies revealed that pharmacological activation of EP4 promoted, whereas inhibition of EP4 suppressed, proliferation and migration of primary-cultured VSMCs. Mechanically, EP4 significantly increased the protein expression of tenascin C (TN-C), a pro-proliferative and pro-migratory extracellular matrix protein, at the translational level. Knockdown of TN-C markedly suppressed EP4 agonist-induced VSMC proliferation and migration. Further studies uncovered that EP4 upregulated TN-C protein expression via the PKA/mTORC1/Ribosomal protein S6 (rpS6) pathway. Together, our findings demonstrate that VSMC EP4 increases TN-C protein expression to promote neointimal hyperplasia via the PKA-mTORC1-rpS6 pathway. Therefore, VSMC EP4 may represent a potential therapeutic target for vascular restenosis. MDPI 2022-08-31 /pmc/articles/PMC9454981/ /pubmed/36078128 http://dx.doi.org/10.3390/cells11172720 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Xu, Hu Fang, Bingying Bao, Chengzhen Mao, Xiuhui Zhu, Chunhua Ye, Lan Liu, Qian Li, Yaqing Du, Chunxiu Qi, Hang Zhang, Xiaoyan Guan, Youfei The Prostaglandin E2 Receptor EP4 Promotes Vascular Neointimal Hyperplasia through Translational Control of Tenascin C via the cAPM/PKA/mTORC1/rpS6 Pathway |
title | The Prostaglandin E2 Receptor EP4 Promotes Vascular Neointimal Hyperplasia through Translational Control of Tenascin C via the cAPM/PKA/mTORC1/rpS6 Pathway |
title_full | The Prostaglandin E2 Receptor EP4 Promotes Vascular Neointimal Hyperplasia through Translational Control of Tenascin C via the cAPM/PKA/mTORC1/rpS6 Pathway |
title_fullStr | The Prostaglandin E2 Receptor EP4 Promotes Vascular Neointimal Hyperplasia through Translational Control of Tenascin C via the cAPM/PKA/mTORC1/rpS6 Pathway |
title_full_unstemmed | The Prostaglandin E2 Receptor EP4 Promotes Vascular Neointimal Hyperplasia through Translational Control of Tenascin C via the cAPM/PKA/mTORC1/rpS6 Pathway |
title_short | The Prostaglandin E2 Receptor EP4 Promotes Vascular Neointimal Hyperplasia through Translational Control of Tenascin C via the cAPM/PKA/mTORC1/rpS6 Pathway |
title_sort | prostaglandin e2 receptor ep4 promotes vascular neointimal hyperplasia through translational control of tenascin c via the capm/pka/mtorc1/rps6 pathway |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9454981/ https://www.ncbi.nlm.nih.gov/pubmed/36078128 http://dx.doi.org/10.3390/cells11172720 |
work_keys_str_mv | AT xuhu theprostaglandine2receptorep4promotesvascularneointimalhyperplasiathroughtranslationalcontroloftenascincviathecapmpkamtorc1rps6pathway AT fangbingying theprostaglandine2receptorep4promotesvascularneointimalhyperplasiathroughtranslationalcontroloftenascincviathecapmpkamtorc1rps6pathway AT baochengzhen theprostaglandine2receptorep4promotesvascularneointimalhyperplasiathroughtranslationalcontroloftenascincviathecapmpkamtorc1rps6pathway AT maoxiuhui theprostaglandine2receptorep4promotesvascularneointimalhyperplasiathroughtranslationalcontroloftenascincviathecapmpkamtorc1rps6pathway AT zhuchunhua theprostaglandine2receptorep4promotesvascularneointimalhyperplasiathroughtranslationalcontroloftenascincviathecapmpkamtorc1rps6pathway AT yelan theprostaglandine2receptorep4promotesvascularneointimalhyperplasiathroughtranslationalcontroloftenascincviathecapmpkamtorc1rps6pathway AT liuqian theprostaglandine2receptorep4promotesvascularneointimalhyperplasiathroughtranslationalcontroloftenascincviathecapmpkamtorc1rps6pathway AT liyaqing theprostaglandine2receptorep4promotesvascularneointimalhyperplasiathroughtranslationalcontroloftenascincviathecapmpkamtorc1rps6pathway AT duchunxiu theprostaglandine2receptorep4promotesvascularneointimalhyperplasiathroughtranslationalcontroloftenascincviathecapmpkamtorc1rps6pathway AT qihang theprostaglandine2receptorep4promotesvascularneointimalhyperplasiathroughtranslationalcontroloftenascincviathecapmpkamtorc1rps6pathway AT zhangxiaoyan theprostaglandine2receptorep4promotesvascularneointimalhyperplasiathroughtranslationalcontroloftenascincviathecapmpkamtorc1rps6pathway AT guanyoufei theprostaglandine2receptorep4promotesvascularneointimalhyperplasiathroughtranslationalcontroloftenascincviathecapmpkamtorc1rps6pathway AT xuhu prostaglandine2receptorep4promotesvascularneointimalhyperplasiathroughtranslationalcontroloftenascincviathecapmpkamtorc1rps6pathway AT fangbingying prostaglandine2receptorep4promotesvascularneointimalhyperplasiathroughtranslationalcontroloftenascincviathecapmpkamtorc1rps6pathway AT baochengzhen prostaglandine2receptorep4promotesvascularneointimalhyperplasiathroughtranslationalcontroloftenascincviathecapmpkamtorc1rps6pathway AT maoxiuhui prostaglandine2receptorep4promotesvascularneointimalhyperplasiathroughtranslationalcontroloftenascincviathecapmpkamtorc1rps6pathway AT zhuchunhua prostaglandine2receptorep4promotesvascularneointimalhyperplasiathroughtranslationalcontroloftenascincviathecapmpkamtorc1rps6pathway AT yelan prostaglandine2receptorep4promotesvascularneointimalhyperplasiathroughtranslationalcontroloftenascincviathecapmpkamtorc1rps6pathway AT liuqian prostaglandine2receptorep4promotesvascularneointimalhyperplasiathroughtranslationalcontroloftenascincviathecapmpkamtorc1rps6pathway AT liyaqing prostaglandine2receptorep4promotesvascularneointimalhyperplasiathroughtranslationalcontroloftenascincviathecapmpkamtorc1rps6pathway AT duchunxiu prostaglandine2receptorep4promotesvascularneointimalhyperplasiathroughtranslationalcontroloftenascincviathecapmpkamtorc1rps6pathway AT qihang prostaglandine2receptorep4promotesvascularneointimalhyperplasiathroughtranslationalcontroloftenascincviathecapmpkamtorc1rps6pathway AT zhangxiaoyan prostaglandine2receptorep4promotesvascularneointimalhyperplasiathroughtranslationalcontroloftenascincviathecapmpkamtorc1rps6pathway AT guanyoufei prostaglandine2receptorep4promotesvascularneointimalhyperplasiathroughtranslationalcontroloftenascincviathecapmpkamtorc1rps6pathway |